Last Week in Biomedicine | May 30 – Jun 5 | Part 2 of 2: Talzenna Prostate Combo, IgG4 Disease First
From a prostate cancer combo that uses your tumor's own broken DNA-repair against it, to the first drug ever to succeed in a rare autoimmune disease called IgG4-related disease — Part 2 of our weekly ...
11 Kesä 16min
Last Week in Biomedicine | May 30 – Jun 5 | Part 1 of 2: Daraxonrasib Pancreatic Cancer, Ivonescimab Lung
The biggest week in cancer research of 2026 dropped at the ASCO meeting in Chicago, and one drug stole the show: a new RAS-blocking pill that nearly doubled survival in metastatic pancreatic cancer, o...
9 Kesä 20min
Last Week in Biomedicine | May 23–29 | Part 2 of 2: Apogee Eczema, TG Therapeutics MS
In Part 2 we cover the remaining clinical trial readouts from the week of May 23–29, 2026 — a Phase 2 atopic dermatitis breakthrough and a Phase 3 multiple sclerosis convenience win.4. Apogee Therapeu...
4 Kesä 11min
Last Week in Biomedicine | May 23–29 | Part 1 of 2: BMS Myeloma, GSK Hep B Cure, Pfizer Lung Cancer
In Part 1 we cover the three biggest clinical trial readouts from the week of May 23–29, 2026 — including two ASCO 2026 opening-day announcements that reshape oncology.1. Bristol Myers Squibb — Mezigd...
2 Kesä 36min
Last Week in Biomedicine | May 18–22 | Part 2 of 2: Bladder Cancer Conjugate, HPV Cervical Win
Part 2 of our May 18–22, 2026 roundup digs into a first-in-class Bicycle Toxin Conjugate for bladder cancer, a non-surgical DNA immunotherapy clearing HPV-driven cervical pre-cancer, anoff-the-shelf c...
28 Touko 12min
Last Week in Biomedicine | May 18–22 | Part 1 of 2: Retatrutide Obesity, Sac-TMT Cancer Win
This week the biggest story in clinical trial results came out of an obesity trial: Eli Lilly's retatrutide — a once-weekly shot that activates three different appetite-and-metabolism hormones (GIP, G...
26 Touko 19min
Last Week in Biomedicine | May 11–15 | Part 2
Top 10 significant clinical trial results from last weekPart 2:6. Enterprise Therapeutics (private) — ETD001 (inhaled ENaCblocker) for cystic fibrosis (Phase 2)7. Daré Bioscience ($DARE) — Ovaprene (h...
21 Touko 23min
Last Week in Biomedicine | May 11–15 | Part 1
Top 10 significant clinical trial results from last weekPart 1:1. REGENXBIO ($RGNX) — RGX-202 microdystrophin gene therapy for Duchenne muscular dystrophy (Phase 3)2. Alkermes ($ALKS) — LUMRYZ (sodium...
19 Touko 12min
